BEDFORD, Mass., Nov. 11, 2015 /PRNewswire/ -- Integral BioSystems LLC will be in the spotlight as an innovative member of the pharmaceutical development CRO community in the Commonwealth of Massachusetts. Unique among firms offering fee-for-services pharmaceutical development, Integral BioSystems also offers clients co-development and licensing opportunities utilizing Integral's proprietary, tissue- and cell-targeted sustained release delivery systems.
The focus of the material to be presented by the firm's CEO/CTO and inventor of the firm's unique drug delivery systems, Dr. Shikha P. Barman, will be her highly innovative drug delivery technologies, OcuSurf™ and NanoM Wafer™. OcuSurf™ allows highly insoluble drug substances to be administered much more effectively than when formulated as simple suspensions. In the words of the inventor: "This delivery system is transformational and has the potential to replace the frequent and less effective administration of poorly soluble drugs formulated as suspensions, with their attendant poorly controlled release profiles, instead offering the drug in a solubilized, sustained-release format." One indication addressed by Integral's NanoM Wafer™ is the treatment of glaucoma by sustained administration of a glaucoma medication. This technology has already gained considerable traction with US and international companies, as well as the NIH, which has awarded a Phase I SBIR Grant to further the product's development. Integral has filed the required IP in support of actively seeking partnerships to co-develop products.
About the Symposium
MassBio CRO/CMO Symposium™ draws attendees from far-and-wide to discuss and evaluate the best alternatives available in R&D services and drug delivery systems with an eye toward shortening time to market and increasing drug substance efficacy. Offered also will be a series of case studies, interactive panel discussions, and networking sessions providing ample time to explore the various techniques and approaches being used by both virtual and established companies.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.
The Company has developed numerous dosage forms for many applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy.
SOURCE Integral BioSystems LLC